Innovimmune Biotherapeutics is focused on developing innovative immunotherapies aimed at treating cancer, autoimmune diseases, and chronic inflammation. The company employs a strategic "Pipeline in a molecule" approach, which allows for the advancement of clinical candidate compounds that have been validated through preclinical proof-of-concept models. This methodology enables the parallel development of multiple drug indications from a single compound, facilitating the potential for multiple Investigational New Drug (IND) and New Drug Application (NDA) approvals. Innovimmune's pipeline includes first-in-class and best-in-class New Chemical Entities (NCEs) that specifically modulate the immune system to enhance therapeutic outcomes for patients.

A key technology utilized by Innovimmune is structure-guided drug design, which integrates computational machine learning and artificial intelligence to identify and develop oral small-molecule medicines. This approach focuses on transforming traditionally intractable disease-associated proteins into viable therapeutic targets. By leveraging structural biology, X-ray crystallography, and medicinal chemistry, Innovimmune designs synthetic compounds that interact with specific protein-ligand binding sites, ensuring high precision and efficacy. The company adheres to the Lipinski Rule-of-Five to optimize drug likeness, minimize toxicity, and enhance bioavailability, ultimately aiming to deliver safe and effective treatments for patients suffering from serious health conditions.

United States

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases.

Follow us on Twitter: @Innovimmune

Innovimmune Biotherapeutics

Company Details